These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2509 related articles for article (PubMed ID: 17199924)
21. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Wu J; Zhu Y; Jiang Y; Cao Y Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522 [TBL] [Abstract][Full Text] [Related]
22. Retinol-binding protein in nonobese women with polycystic ovary syndrome. Lee JW; Im JA; Lee DC; Lee HR; Shim JY Clin Endocrinol (Oxf); 2008 May; 68(5):786-90. PubMed ID: 17986278 [TBL] [Abstract][Full Text] [Related]
23. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Chae SJ; Kim JJ; Choi YM; Hwang KR; Jee BC; Ku SY; Suh CS; Kim SH; Kim JG; Moon SY Hum Reprod; 2008 Aug; 23(8):1924-31. PubMed ID: 18579512 [TBL] [Abstract][Full Text] [Related]
24. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. Diamanti-Kandarakis E; Kouli CR; Bergiele AT; Filandra FA; Tsianateli TC; Spina GG; Zapanti ED; Bartzis MI J Clin Endocrinol Metab; 1999 Nov; 84(11):4006-11. PubMed ID: 10566641 [TBL] [Abstract][Full Text] [Related]
25. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Ardawi MS; Rouzi AA Fertil Steril; 2005 Jun; 83(6):1708-16. PubMed ID: 15950640 [TBL] [Abstract][Full Text] [Related]
26. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome. Toscani MK; Mario FM; Radavelli-Bagatini S; Spritzer PM Nutr Res; 2011 Feb; 31(2):97-103. PubMed ID: 21419313 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. Lankarani M; Valizadeh N; Heshmat R; Peimani M; Sohrabvand F Gynecol Endocrinol; 2009 Aug; 25(8):504-7. PubMed ID: 19499403 [TBL] [Abstract][Full Text] [Related]
28. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents. Glueck CJ; Morrison JA; Friedman LA; Goldenberg N; Stroop DM; Wang P Metabolism; 2006 Apr; 55(4):508-14. PubMed ID: 16546482 [TBL] [Abstract][Full Text] [Related]
29. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091 [TBL] [Abstract][Full Text] [Related]
30. Is prostate-specific antigen a potential new marker of androgen excess in polycystic ovary syndrome? Vural B; Ozkan S; Bodur H J Obstet Gynaecol Res; 2007 Apr; 33(2):166-73. PubMed ID: 17441890 [TBL] [Abstract][Full Text] [Related]
31. Serum ghrelin level in women with polycystic ovary syndrome and its relationship with endocrine and metabolic parameters. Mitkov M; Pehlivanov B; Orbetzova M Gynecol Endocrinol; 2008 Nov; 24(11):625-30. PubMed ID: 19031219 [TBL] [Abstract][Full Text] [Related]
32. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Panidis D; Farmakiotis D; Rousso D; Katsikis I; Delkos D; Piouka A; Gerou S; Diamanti-Kandarakis E Eur J Intern Med; 2008 Oct; 19(6):406-12. PubMed ID: 18848173 [TBL] [Abstract][Full Text] [Related]
33. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population. Pehlivanov B; Orbetzova M Gynecol Endocrinol; 2007 Oct; 23(10):604-9. PubMed ID: 17852429 [TBL] [Abstract][Full Text] [Related]
34. Body fat composition and distribution in women with polycystic ovary syndrome. Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379 [TBL] [Abstract][Full Text] [Related]
35. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421 [TBL] [Abstract][Full Text] [Related]
36. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity. Słopień R; Lewandowski K; Kolacz E; Zawilska K; Warenik-Szymankiewicz A Gynecol Endocrinol; 2006 Nov; 22(11):651-4. PubMed ID: 17145652 [TBL] [Abstract][Full Text] [Related]
37. Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40. Liang SJ; Hsu CS; Tzeng CR; Chen CH; Hsu MI Hum Reprod; 2011 Dec; 26(12):3443-9. PubMed ID: 21926412 [TBL] [Abstract][Full Text] [Related]
38. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome]. Ye BL; Yang HY; Zhao JZ; Lin JJ; Lin WQ Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):745-8. PubMed ID: 14728846 [TBL] [Abstract][Full Text] [Related]
39. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Mitkov M; Pehlivanov B; Terzieva D Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262 [TBL] [Abstract][Full Text] [Related]
40. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Spranger J; Möhlig M; Wegewitz U; Ristow M; Pfeiffer AF; Schill T; Schlösser HW; Brabant G; Schöfl C Clin Endocrinol (Oxf); 2004 Dec; 61(6):738-46. PubMed ID: 15579189 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]